Amresh Kumar - 14 Apr 2025 Form 4 Insider Report for Grace Therapeutics, Inc. (GRCE)

Reporting relationship: VP Program Management
Issuer ticker: GRCE
Reported as of: 14 Apr 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Apr 2025, 20:58:53 UTC
Prior SEC filing: 08 May 2024
Next SEC filing: 01 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Robert DelAversano as attorney-in-fact for Amresh Kumar

Key filing fact

Amresh Kumar filed Form 4 for Grace Therapeutics, Inc. (GRCE) on 16 Apr 2025.

Key facts

This page summarizes Amresh Kumar's Form 4 filing for Grace Therapeutics, Inc. (GRCE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Apr 2025, 20:58.

Change

Previous filing in this sequence was filed on 08 May 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GRCE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +30,000
Change %
Price: $0.000000
Shares after: 30,000
Date: 14 Apr 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $2.08
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option vests quarterly in substantially equal installments over a 3-year period, subject to the Reporting Person's continuous service as of each vesting date.

SEC remarks

Exhibit 24: Power of Attorney